Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
The slogan for this year's World Blood Donor Day campaign is 'Give blood, give plasma, share life, share often'
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Subscribe To Our Newsletter & Stay Updated
